NCT01228136

Brief Summary

The purpose of this study is to determine if the use of tranexamic acid prior adenotonsillectomy in children can reduce surgical and postoperative bleeding.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Jan 2010

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2010

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 22, 2010

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 26, 2010

Completed
6 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2010

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

December 22, 2010

Status Verified

October 1, 2010

Enrollment Period

10 months

First QC Date

October 22, 2010

Last Update Submit

December 21, 2010

Conditions

Keywords

AdenotonsillectomyTranexamic acidBlood lossPostoperative hemorrhage

Outcome Measures

Primary Outcomes (1)

  • volume of intraoperative bleeding

    intraoperative bleeding (in mL of aspirated blood) measured at the end of the surgical procedure

    one day

Secondary Outcomes (1)

  • incidence of postoperative bleeding

    ten days

Study Arms (2)

Tranexamic acid

ACTIVE COMPARATOR
Drug: Tranexamic Acid

Placebo

PLACEBO COMPARATOR
Other: normal saline solution

Interventions

10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose

Also known as: Transamin, Hemoblock
Tranexamic acid

normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose

Placebo

Eligibility Criteria

Age4 Years - 12 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • children with 4 to 12 years
  • adenotonsillar hypertrophy
  • indication of adenotonsillectomy

You may not qualify if:

  • patients with blood dyscrasia
  • patients with history of bleeding of difficult control or spontaneous hematoma
  • patients with coagulation tests altered
  • patients with evidence of hematopoietic, cardiovascular, hepatic, renal, neurologic, psychiatric or auto immune disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital da Criança Santo Antônio

Porto Alegre, Rio Grande do Sul, 90035-074, Brazil

Location

Related Publications (1)

  • Brum MR, Miura MS, Castro SF, Machado GM, Lima LH, Lubianca Neto JF. Tranexamic acid in adenotonsillectomy in children: a double-blind randomized clinical trial. Int J Pediatr Otorhinolaryngol. 2012 Oct;76(10):1401-5. doi: 10.1016/j.ijporl.2012.04.028. Epub 2012 Jun 16.

MeSH Terms

Conditions

HemorrhagePostoperative Hemorrhage

Interventions

Tranexamic AcidSaline Solution

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsPostoperative Complications

Intervention Hierarchy (Ancestors)

Cyclohexanecarboxylic AcidsAcids, CarbocyclicCarboxylic AcidsOrganic ChemicalsCrystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical Preparations

Study Officials

  • Marília R Brum, MD

    Irmandade Santa Casa de Misericórdia de Porto Alegre

    PRINCIPAL INVESTIGATOR
  • José Faibes Lubianca Neto, MD

    Irmandade Santa Casa de Misericórdia de Porto Alegre

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 22, 2010

First Posted

October 26, 2010

Study Start

January 1, 2010

Primary Completion

November 1, 2010

Study Completion

December 1, 2010

Last Updated

December 22, 2010

Record last verified: 2010-10

Locations